About One Lambda
As a brand of Thermo Fisher Scientific, One Lambda‘s commitment is to provide the most consistent and reliable reagents. The driving force behind our product development and educational programs is facilitating a new standard of care in transplant monitoring. We develop and distribute a comprehensive line of HLA typing and antibody detection products, laboratory instrumentation, and computer software that are used to simplify and automate testing procedures and final test evaluations. Our diagnostic tests are used by transplant centers worldwide to determine the compatibility of donors and recipients pre-transplant, and post-transplant to detect the presence of antibodies that can lead to transplant rejection.
At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.
DKMS is an international non-profit organization, founded 25 years ago in Germany by Dr. Peter Harf when he lost his wife Mechtild to leukemia. Peter promised her that he would help every blood cancer patient find a matching donor. At that time, there were only 3,000 potential stem cell donors available to provide a transplant in Germany and within one year of founding DKMS, the number of stem cell donors increased to 68,000. Today, DKMS has offices in Germany, the United States (opened 2004), Poland (2009), Spain (2011) and the UK (2013) and has registered over 6 million potential donors worldwide. DKMS has over 600 staff members from 20 countries dedicated to helping give every blood cancer patient a second chance at life. DKMS is driven by innovation and invests in our people’s ideas in order to be the premier provider of assistance to blood cancer patients throughout the world.
Histogenetics, based in New York, USA, is an international leader in molecular HLA typing. Histogenetics mastered Next Generation (NGS) and Third generation sequencing technologies (PacBio) for routine HLA typing for ultimate resolution and quality at high volume. Histogenetics’ mission is integrating and adopting technologies for ultimate high resolution HLA typing that could advance patient care and science.
Immucor is dedicated to offering products that enable patients anywhere who are in need of blood or an organ to receive the right match that is safe, accessible and affordable.
The result is life changing for a patient in need of a transfusion or transplant.
Immucor is a leading provider of transfusion and transplantation diagnostic products worldwide. Our new corporate identity illustrates the right match of donors with patients in need of blood or an organ as well as Immucor’s partnership with healthcare organizations in need of innovation and productivity.
We lead the fields of transfusion and transplantation medicine by advancing science and technology. We provide hope for the future by teaching the medical leaders of tomorrow. We enhace lives by connecting donors to patients every day.
A Brief History
Stanford Blood Center was created within the Department of Pathology at Stanford University School of Medicine in 1978. The Blood Center was created to meet the increasingly large and complex transfusion needs of Stanford Hospital and Lucile Salter Packard Children’s Hospital at Stanford, and to perform research and teaching.
A LEADER IN THE BIOMEDICAL REVOLUTION, Stanford Medicine has a long tradition of leadership in pioneering research, creative teaching protocols and effective clinical therapies. Our close proximity to the resources of the university—including the Schools of Business, Law, Humanities and Sciences and Engineering—our seamless relationship with our affiliated adult and children’s hospitals and our ongoing associations with the entrepreneurial endeavors of Silicon Valley make us uniquely positioned to accelerate the pace at which new knowledge is turned into tangible health benefits.
The American Society for Histocompatibility and Immunogenetics (ASHI) is a not-for-profit association of clinical and research professionals including immunologists, geneticists, molecular biologists, transplant physicians and surgeons, pathologists and technologists. As a professional society involved in histocompatibility, immunogenetics and transplantation, ASHI is dedicated to advancing the science and application of histocompatibility and immunogenetics; providing a forum for the exchange of information; and advocating the highest standards of laboratory testing in the interest of optimal patient care.
The American Society for Histocompatibility and Immunogenetics is an international society of professionals dedicated to advancing the science, education and application of immunogenetics and transplant immunology.
ASHI is the foremost authority and leading educational resource in immunogenetics and histocompatibility. Our vision is to improve the quality of human life and health through the translation and implementation of scientific innovations to clinical practice.